




Overview on ongoing RCLs in TAVI ?


Prof. Patrizio LANCELLOTTI, MD, PhD, FESC, FACC, Heart Valve Clinic, University of Liège, CHU Sart Tilman, BELGIUM

Disclosure related to this presentation: None


Evidence Base Derived From Clinical Trials



Evidence Base Derived From Clinical Trials



Evidence Base Derived From Clinical Trials




TAVI and Guidelines: European and US Timeline




META-ANALYSIS OF RCTS

Pagnesi et al JACC Cardiovasc Interv. 2017 Sep 25;10(18):1899-1901




2017 ESC/EACTS Guidelines for the Management of AS: Update in Risk Categorization

STS >15%




"The favourable results of TAVI have been reproduced in multiple large-scale, nationwide registries supporting the generalizability of outcomes observed in randomized controlled trials. This favours the use of TAVI over surgery in elderly patients at increased surgical risk. However, the final decision between SAVR and TAVI (including the choice of access route) should be made by the Heart Team."

2017 ESC/EACTS Guidelines for the Management of AS: Update in Risk Categorization



"The favourable results of TAVI have been reproduced in multiple large-scale, nationwide registries supporting the generalizability of outcomes observed in randomized controlled trials. This favours the use of TAVI over surgery in elderly patients at increased surgical risk. However, the final decision between SAVR and TAVI (including the choice of access route) should be made by the Heart Team."

Level of Evidence Pertaining to Prosthetic Valve Management ACC/AHA-2017 and ESC-2017 guidelines



A=level of evidence 'A', B=level of evidence 'B', C=level of evidence 'C'

Gaps in Evidence: Expanding Clinical Indications

Gaps in Evidence: Expanding Clinical Indications

LOW RISK PATIENTS



Evolut R Low Risk Trial NCT02701283 **NOTION-2** NCT02825134

ASYMPTOMATIC PATIENTS


EARLY TAVR TRIAL

MODERATE AORTIC STENOSIS AND CONGESTIVE HEART FAILURE

TAVR UNLOAD TRIAL

The PARTNER 3 Trial Study Design





Follow-up: 30 days, 6 mos, 1 year and annually through 10 years

MEDTRONIC TAVR RCT IN LOW RISK PATIENTS


TRIAL DESIGN & LEAFLET SUB-STUDY

Patient Population: Low Risk Cohort

Determined by Heart Team to be low surgical risk


Primary Endpoint:

- Safety: Death, all stroke, life-threatening bleeding, major vascular complications, or AKI at 30 days
- Efficacy: Death or major stroke at 2 years
- Sample Size: ~1200 Subjects
- Follow-up Evaluations:
 30-days, 6-month, 18-month, and 1 thru 5 years
- Number of Sites: Up to 80 sites






Asymptomatic AS: When Should We Offer AVR?



EARLY TAVR Trial

Flow Chart






Primary Endpoint (superiority): 2-year composite of all-cause death, all stroke, and repeat cardiovascular hospitalization

Principal Investigators: Philippe Généreux, MD, Robert Bonow, MD


Moderate AS with Low LVEF and HF (Stage B2?)



100mm/s 57bpm



TAVR UNLOAD Trial Study Design (600 patients, 1:1 Randomized)



- NewYork-Presbyterian



Columbia University Medical Center





INSTITUT UNIVERSITAIRE DE CARDIOLOGIE ET DE PNEUMOLOGIE DE QUÉBEC




Gaps in Evidence: Off-Label Use

→ Bicuspid Anatomy

→ Failes Surgical Prosthesis

Why Bicuspids are Problematic for TAVR?

- Bulky Eccentric Calcification
 - Incomplete valve expansion
 - Paravalvar leak
 - Annulus rupture
 - Higher PPM Rate
- Abnormal/lower coronary orifices
- Ascending Aortopathy- 25%
 - Needs Treatment
 - Risk of rupture/dissection
- Ovality of annulus
 - Risk of paravalvar leak
 - Long-term durability of the TAVI valve?
- For these reasons bicuspid valves had been excluded from all randomized trials
- Relative contraindication for TAVI according to guidelines



TAVI in Bicuspid Anatomy BIVOLUTX

Bicuspid aortic Valves with eVOLUT platform international eXperience

Pl's: Didier Tchétché, Toulouse /Nicolas van Mieghem, Rotterdam


Design: Prospective registry

Endpoint: Valve performance and VARC-2 outcomes at 30 days and 1 year

Centres: Up to 20 European Centers


Update: 10/150 patients recruited

Metanalysis of Transcatheter Valve-in-Valve Implantation Versus Redo Aortic Valve Surgery for Bioprosthetic Aortic Valve Dysfunction




 This meta-analysis of non-randomized studies with modest number of patients suggested that ViV-TAVI had similar 30-day survival compared with redo-SAVR for aortic BPV dysfunction TAVI Procedure: – Will cerebral embolic protection become the standard for TAVR in the future?


TAVI Procedure and CerebroVascular Events



TAVI Procedure and CerebroVascular Events




TAVI Procedure and CerebroVascular Events



Stortecky, Windecker. Circulation 2012;126:2921-4


Embolic Protection Devices and TAVI



Cerebral Embolic Protection During TAVR




A Clinical Event Meta-Analysis




 "In conclusion, the totality of the data suggests that use of EP during TAVR appears to be associated with a non-significant trend towards reduction in death or stroke."

JACC 2017;31:463-70



REFLECT US IDE Trial

A prospective multicenter randomized trial of TriGuard[™] neuro protection vs no protection in patients undergoing TAVR at clinical centers in EU and US PI: Jeff Moses and Andreas Baumbach



Secondary Safety Endpoint

VARC Device safety at 30 days


Primary Efficacy Endpoint Total Volume of new DWMRI Lesions


MACCE: Composite of all cause death, Stroke, life threatening bleed, AKI 2-3, major vascular complications

TAVR Adjunct Pharmacology Customized Patient-Based Therapy

Makkar RR et al. N Engl J Med 2015


- Incidence: 17 of 132 patients (13%)
- Reduced incidence with oral anticoagulation (0% vs 29%, p=0.04)
 Restoration of leaflet motion in all 11 patients who received oral anticoagulation
- Higher incidence of stroke/TIA in patients with leaflet motion abnormality (18% vs 1%, p=0.007)






Chakravarty et al. Lancet 2017

- 890 patients with interpretable CT scans were included (RESOLVE registry, n=626; SAVOR Registry, n=264)
- Incidence: 12%: 4% after SAVR and 13% after TAVR (p<0.001)



Chakravarty et al. Lancet 2017



Chakravarty et al. Lancet 2017

	Normal leaflet motion (N=784)		Reduced leaflet motion (N=106)			_
	n/N (%)	Rate per 100 person-years	n/N (%)	Rate per 100 person-years	Hazard ratio (95% CI)	p-value
All events						
Death	34/784 (4.3%)	2.91	4/106 (3.8%)	2.66	0,96 (0.34-2.72)	0.94
Myocardial infarction	4/784 (0.5%)	0.34	1/106 (0.9%)	0.67	1.91 (0.21-17.08)	0.56
Strokes/TIAs	27/784 (3.4%)	2.36	11/106 (10.4%)	7.85	3.27 (1.62-6.59)	0.001
All strokes*	22/784 (2.8%)	1.92	6/106 (5.7%)	4.12	2.13 (0.86-5.25)	0.10
Ischemic strokes	21/784 (2.7%)	1.83	6/106 (5.7%)	4.12	2.23 (0.90-5.53)	0.08
TIAs	7/784 (0.9%)	0.60	6/106 (5.7%)	4,18	7.02 (2.35-20.91)	0.0005
TIA=Transient ischemic attack						

TIA-Transient ischemic attack


* All strokes include hemorrhagic and ischemic strokes

TAVR Adjunct Pharmacology Customized Patient-Based Therapy

BEFORE	DURING	AFTER	
Acetylsalicylic acid (ASA)	<section-header><text><text><image/><image/></text></text></section-header>	<section-header><section-header><section-header><section-header><section-header><section-header><section-header><section-header><text></text></section-header></section-header></section-header></section-header></section-header></section-header></section-header></section-header>	

AntiThrombotic Therapy


Adapted from Capodanno et JACC Cardiovasc Interv. 2017 Jul 10;10(13):1366-1369



POPULAR-TAVI

Nijenhuis et al. Am Heart J 2016;173:77-85


Study Hypothsis: Monotherapy with Aspirin or OAC monotherapy is safer (nonprocedure-related bleeding) than the addition of clopidogrel for 3 months



Recruitment began in February 2014, and the trial will continue until a total of 1,000 patients (684 expected in cohort A and 316 in cohort B) are included and followed up for 1 year.

ATLANTIS (Anti-Thrombotic Strategy to Lower All cardiovascular and Neurologic

Ischemic and Hemorrhagic Events after **T**rans-Aortic Valve Implantation for Aortic **S**tenosis)




Primary end-point is a composite of death, MI, stroke, systemic emboli, intracardiac or bioprosthesis thrombus, episode of deep vein thrombosis or pulmonary embolism,major bleedings over one year follow-up.

*2.5mg bid if creatinine clearance 15-29mL/min or if two of the following criteria: age≥80 years, weight≤60kg or creatinine≥1,5mg/dL (133μMol).

The **GALILEO** Study design


Global study comparing a rivAroxaban-based antithrombotic strategy to an antipLatelet-based strategy after transcatheter aortIc vaLve rEplacement to Optimize clinical outcomes



Discharge: The "minimalist" TAVR procedure strategy has become imbedded as a preferred treatment approach in the majority of patients




To evaluate the efficacy, feasibility, and safety of next day discharge home in patients undergoing balloon-expandable transfemoral TAVR utilizing the Vancouver 3M Clinical Pathway




GAPS IN IMPLEMENTATION: GEOGRAPHICAL DISPERSION AND SOCIOECONOMIC INEQUALITIES - TAVI


Pilgrim T et al. Eur Heart J 2018




Estimates for Q1–Q4 2017 (Western Europe) or Q4 2016–Q3 2017 (all other regions) including moving annual total (MAT) data. Data are subject to end of year adjustment.



Gaps in Evidence







- Expanding Clinical Indications
 - Low risk
 - Asymptomatic pts.
 - Moderate AS with CHF
 - Off-Label Use
 - Bicuspid Anatomy
 - Pure Native Aortic Regurgitation
 - Failes Surgical Prosthesis
- TAVI Procedure
 - Cerebral Protection
 - Valve Thrombosis \rightarrow Anticoagulation
- Others
 - Valve Durability
 - Geographic inequalities
 - Comparision between valves

Thanks